0001209191-18-028866.txt : 20180509
0001209191-18-028866.hdr.sgml : 20180509
20180509162415
ACCESSION NUMBER: 0001209191-18-028866
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180507
FILED AS OF DATE: 20180509
DATE AS OF CHANGE: 20180509
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SARGEN GREGORY
CENTRAL INDEX KEY: 0001227835
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10638
FILM NUMBER: 18818640
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CAMBREX CORP
CENTRAL INDEX KEY: 0000820081
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 222476135
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MEADOWLANDS PLZ
CITY: E RUTHERFORD
STATE: NJ
ZIP: 07073
BUSINESS PHONE: 2018043000
MAIL ADDRESS:
STREET 1: ONE MEADOWLANDS PLAZA
CITY: E. RUTHERFORD
STATE: NJ
ZIP: 07073
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-05-07
0
0000820081
CAMBREX CORP
CBM
0001227835
SARGEN GREGORY
ONE MEADOWLANDS PLAZA
EAST RUTHERFORD
NJ
07073
0
1
0
0
EVP, Corporate Development
Common Stock
2018-05-07
4
A
0
30000
0.00
A
50000
D
Common Stock
2018-05-07
4
S
0
23002
49.4618
D
26998
D
Common Stock
2018-05-08
4
A
0
7500
16.905
A
34498
D
Common Stock
2018-05-08
4
A
0
7500
17.81
A
41998
D
Common Stock
2018-05-08
4
A
0
15000
41.36
A
56998
D
Common Stock
2018-05-08
4
A
0
7500
40.65
A
64498
D
Common Stock
2018-05-08
4
S
0
10565
49.05
D
53933
D
Common Stock
2018-05-08
4
S
0
33933
49.6254
D
20000
D
Stock Option (right to buy)
16.905
2018-05-08
4
M
0
7500
0.00
A
2020-10-28
Common Stock
7500
0
D
Stock Option (right to buy)
17.81
2018-05-08
4
M
0
7500
0.00
A
2021-10-22
Common Stock
7500
7500
D
Stock Option (right to buy)
41.36
2018-05-08
4
M
0
15000
0.00
A
2022-10-21
Common Stock
15000
15000
D
Stock Option (right to buy)
40.65
2018-05-08
4
M
0
7500
0.00
A
2023-10-26
Common Stock
7500
22500
D
Pursuant to settlement of a performance share award.
Broker-assisted sale of which 14,805 shares were to cover the payment of withholding tax liability from the settlement of a performance share award.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.20 to $49.875 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.50 to $49.45 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 4 to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.50 to $49.85 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 5 to this Form 4.
The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 28, 2014, which was the first anniversary of the date on which the option was granted.
The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 22, 2015, which was the first anniversary of the date on which the option was granted.
The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 22, 2016, which was the first anniversary of the date on which the option was granted.
The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 26, 2017, which was the first anniversary of the date on which the option was granted.
Danielle Mann for Gregory Sargen by POA
2018-05-09